Tasca Therapeutics

Executive Summary

Tasca Therapeutics is a preclinical-stage biotechnology company pioneering novel cell therapies for solid tumors. Founded in 2021 and headquartered in San Francisco, the company has raised $52 million to develop its proprietary T-cell engineering platform designed to enhance tumor-homing and persistence, addressing the critical unmet need in oncology beyond hematological malignancies. Tasca's approach aims to overcome key limitations of current cell therapies, such as poor infiltration and exhaustion in the solid tumor microenvironment. With a strong focus on innovation, the company is positioned to advance a pipeline of engineered T-cell candidates toward clinical development, leveraging its platform to potentially improve patient outcomes in difficult-to-treat solid tumors.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Candidate70% success
• Q4 2026Preclinical Data Presentation at Major Conference85% success
• Q3 2026Series B Financing or Partnership Announcement60% success